Alembic Pharmaceuticals Ltd

Appointment details

• Mr. Chirag Shukla appointed as Company Secretary and Compliance Officer (KMP).
• Effective date: 20 August 2026.
• Reason: Appointment to fill governance role.
• Profile: CS and Law graduate with 19+ years' experience.
• Previous roles: Deepak Phenolics Limited; Schaeffler India Limited; Alembic Limited; Bhavnagar Energy.
• Expertise: Companies Act, SEBI Regulations, governance, corporate restructuring.
• Disclosure: Not Applicable for relationships with directors or promoters.
• KMP status conferred to the CS appointment.

Meeting Details

• Date and event: 04 August 2026 Q1 FY27 Earnings Conference Call.
• Mode: Virtual, group call for analysts/investors.
• Organizer: Alembic Pharmaceuticals Limited.

Participants

• Key company participants: MD, CFO, Head of Investor Relations and Corporate Development.

Purpose

• Discuss Q1 FY27 performance, outlook, and strategic developments; investor/analyst questions invited.

Additional Notes

• Transcript of the call enclosed; recording of the conference is available.

AGM Details

• AGM held on 5 August 2026 at 4:00 PM IST via VC/OAVM.
• Quorum present; 78 Members attended.
• Voting results to be declared by 7 August 2026.

Ordinary Business

• Adopt Audited Standalone Financial Statements for year ended 31 March 2026.
• Adopt Audited Consolidated Financial Statements for year ended 31 March 2026.
• Declare dividend on equity shares for FY 2025-26.
• Re-appoint director retiring by rotation: Pranav Amin.

Special Business

• Appoint Independent Director: Sujit Jaysukh Bhayani.
• Ratify remuneration to Cost Auditors for FY 2026-27.

Meeting Details

• Date and time: 4 August 2026, 5:30 PM IST.
• Type and mode: post-results conference call; virtual.
• Event/organiser: Alembic Pharmaceuticals post-results conference call.
• Participants: Senior Management Team Members.

Purpose

• Purpose: discuss Q1 FY27 unaudited financial results.

Regulatory update

• USFDA Warning Letter dated 10 July 2026 issued to the Clinical Investigator at the Vadodara facility.
• Observation concerns Informed Consent Form (ICF) for a bioequivalence study; not tied to data integrity.
• Company preliminarily finds no material financial impact; coordinating with investigator to prepare a response.
• Inspection held Mar 3-7, 2025; prior disclosure noted in 2025.
• No operations restriction at Bioequivalence Facility per preliminary assessment.